Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis

Ann Rheum Dis. 2009 Aug;68(8):1367-8. doi: 10.1136/ard.2008.099093.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antirheumatic Agents / adverse effects*
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / genetics*
  • Cytochrome P-450 CYP1A2 / genetics
  • Dihydroorotate Dehydrogenase
  • Female
  • Humans
  • Isoxazoles / adverse effects*
  • Leflunomide
  • Male
  • Middle Aged
  • Oxidoreductases Acting on CH-CH Group Donors / genetics*
  • Polymorphism, Genetic

Substances

  • Antirheumatic Agents
  • Dihydroorotate Dehydrogenase
  • Isoxazoles
  • CYP1A2 protein, human
  • Cytochrome P-450 CYP1A2
  • Oxidoreductases Acting on CH-CH Group Donors
  • Leflunomide